Immunohisto Chemistry Advancements Offer More Accurate in Mesothelioma Diagnosis
Malignant mesothelioma is a unusual and aggressive tumor for which no successful therapy has been discovered despite the breakthrough of many potential molecular and genetic targets. The late stage of Malignant pleural mesothelioma diagnosis and the long latency that exists between exposures and diagnosis have made it tricky to completely evaluate what risk factors do and the resulting molecular effects.
Many medical centers are now seeing increasing numbers of patients with malignant mesothelioma. This gives pathologists diagnosing the patient many problems, which can be separated into those encountered in making the distinction between cancer of the mesothelium and harmless changes and those experienced in differentiating malignant mesotheliomas from other sorts of e-cadherin and connective tissue tumours. IHC performs a major role in making the diagnosis, however, it should be understood with regards to the medical setting and radiological characteristics, and taking into consideration the extensive morphological differences existing in mesothelioma.
Malignant mesothelioma is a cancer directly affecting the serosal cavities, an anatomical location that is often affected by metastatic disease, mostly from primary carcinomas of the ovary, lung and breast. Developments in immunohistochemistry have lead to improved diagnostic sensitivity and cancer of the mesothelium in both cytological and histological material. As of late, the authors group employed high throughput technology to the classification of new markers that might assist in being able to tell the difference between malignant mesothelioma from ovarian and peritoneal serous carcinoma, tumors with closely related histogenesis and antigenic profile. Together with the better tools accessible for serosal cancer diagnosis, knowing the biology of cancer of the mesothelium has accumulate lately.
